Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Sprint Bioscience

1,53 SEK

-4,09 %

Mindre end 1K følgere

SPRINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-4,09 %
+116,62 %
+150,00 %
+264,83 %
-1,98 %
-7,59 %
+143,06 %
-75,85 %
-87,01 %

Sprint Bioscience is a research company. The company develops drug candidates that can fight cancer individually or in combination with other drugs. The company has a portfolio of projects that are focused on attacking parts of the processes of cancer cells. The business model is based on a project portfolio and developing projects in parallel in the preclinical phase and then entering into licensing agreements with the global pharmaceutical industry. The company is headquartered in Huddinge.

Læs mere
Markedsværdi
160,91 mio. SEK
Aktieomsætning
1,23 mio. SEK
Omsætning
65,64 mio.
EBIT %
-29,97 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
11.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse5.12.2025, 07.58

Redeye: Sprint Bioscience (Q3 review) - Gilead deal a strong confirmation

Sprint Bioscience
Pressemeddelelse27.11.2025, 13.17

BioStock: Sprint Bioscience: ”We have shown it's possible to make early deals”

Sprint Bioscience
Pressemeddelelse24.11.2025, 14.23

BioStock: Sprint Bioscience sells cancer program TREX1 to Gilead

Sprint Bioscience

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse24.11.2025, 05.08

Sprint Bioscience sells the TREX1 program to Gilead

Sprint Bioscience
Pressemeddelelse19.11.2025, 07.17

BioStock: Video from Sprint Bioscience's presentation at BioStock Life Science Summit 2025

Sprint Bioscience
Pressemeddelelse4.9.2025, 09.05

Redeye: Sprint Bioscience - A clear objective to secure a new partner

Sprint Bioscience
Pressemeddelelse26.6.2025, 14.45

Sprint Bioscience’s DCPS data published in Leukemia

Sprint Bioscience
Selskabsmeddelelse18.6.2025, 17.18

Sprint Bioscience collaborates to expand its MASH programme into inflammation

Sprint Bioscience
Pressemeddelelse30.5.2025, 09.37

Redeye: Sprint Bioscience - Increased pressure ahead of the next sprint baton-exchange

Sprint Bioscience
Pressemeddelelse4.3.2025, 09.30

Sprint Bioscience presents the VPS34 program at two scientific conferences

Sprint Bioscience
Pressemeddelelse17.2.2025, 09.30

Sprint Bioscience presents preclinical data from the TREX1 program at AACR IO

Sprint Bioscience
Pressemeddelelse13.2.2025, 10.51

Redeye: Sprint Bioscience Q4 - Confident expansion

Sprint Bioscience
Pressemeddelelse8.1.2025, 12.00

Sprint Biosciences upcoming activities

Sprint Bioscience
Pressemeddelelse18.12.2024, 07.30

Sprint Bioscience adds new cancer drug program to portfolio

Sprint Bioscience
Pressemeddelelse4.11.2024, 10.00

Sprint Bioscience will present at the BioStock Life Science Summit, November 21

Sprint Bioscience
Pressemeddelelse31.10.2024, 08.27

Redeye: Sprint Bioscience Q3 - Steady sales and continued progress

Sprint Bioscience
Pressemeddelelse9.10.2024, 06.37

BioStock: Sprint Bioscience CEO comments on deal potential

Sprint Bioscience
Pressemeddelelse30.8.2024, 07.15

Redeye: Sprint Bioscience Update - Robust sales and project activity

Sprint Bioscience
Pressemeddelelse10.5.2024, 10.35

Redeye: Sprint Bioscience - Improved sales and activity

Sprint Bioscience
Pressemeddelelse11.4.2024, 13.15

Positive preclinical results in Sprint Bioscience's oncology program targeting TREX1

Sprint Bioscience
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.